Gelonghui November 12th | Jiangsu NHWA Pharmaceutical (002262.SZ) announced that the company recently received the Approval Notice for Clinical Trial of Category 1 Chemical Drug NH160030 Tablet in 4 specifications issued by the National Medical Products Administration (referred to as the "NMPA"), and will conduct clinical trials in the near future.
NH160030 is an oral selective μ-opioid receptor agonist, a new generation of opioid analgesics. Preclinical trial results have shown that compared to commonly used opioid analgesics such as morphine and hydrocodone, it has superior efficacy and fewer side effects. NH160030 is derived from internal independent research and development, and the company exclusively owns its intellectual property. According to the requirements of China's drug registration laws and regulations, after obtaining the Approval Notice for Clinical Trial of the drug, clinical trials need to be conducted and approved by the NMPA before production and listing.